Today, Revvity, Inc. (NYSE: RVTY) has unveiled the Signals ClinicalTM solution through its software and informatics division, Revvity Signals. This groundbreaking software-as-a-service (SaaS) platform is designed to revolutionize clinical trial data management, offering comprehensive insights to facilitate informed decision-making and accelerate the delivery of therapeutic treatments to market. By integrating with Spotfire visual analytics, Signals Clinical promises to redefine how the pharmaceutical, biotechnology, and contract research sectors approach clinical trial data analysis, providing unparalleled access and insight to drive advancements in clinical development and therapeutic innovations.
Kevin Willoe, Senior Vice President, and General Manager of Revvity Signals Software, Inc., highlighted the transformative potential of Signals Clinical, stating, “In the critical domains of pharmaceuticals, biotechnology, and contract research, expediting the introduction of new treatments is paramount. Signals Clinical addresses the industry’s pressing need for a solution that prioritizes patient safety while empowering data-driven decision-making through real-time analytics. By combining this platform with advanced data visualization tools, we empower our clients to navigate the complexities of clinical development more efficiently, ultimately expediting the delivery of new drugs to patients.”
Centralizing Clinical Data for Informed Decision-Making
Signals Clinical serves as a centralized repository for all clinical trial data, granting self-service access to users for a comprehensive view of patient safety, treatment efficacy, and trial progress. This consolidation enables rapid insights, facilitating faster and more informed clinical decisions, thereby significantly shortening the time-to-market for critical therapeutics.
Empowering Life Sciences with Advanced Analytics
Combining Signals Clinical with Spotfire not only streamlines data preparation but also enhances strategic analyses such as safety and efficacy assessments. By reducing manual data handling efforts, Signals Clinical allows organizations to focus on delivering crucial clinical trial insights and fostering collaborative efforts across functions.
Leading with FAIR Practices for Enhanced Data Management
Built on FAIR principles, the platform simplifies data preparation, minimizes effort, and maximizes value. It offers customizable workflows for data management, clinical review, and study monitoring, along with integrated collaboration tools. These features facilitate documentation and referencing of queries by study managers, enhancing collaboration and efficiency among clinical researchers.
Revvity Signals Software will introduce the Signals Clinical platform for the first time at the 15th Annual SCOPE conference (Booth #236), taking place from February 11-14 in Orlando, Florida.
About Revvity
Revvity thrives on challenging the status quo, turning impossibilities into inspiration and overcoming obstacles with determination. Offering health science solutions, technologies, expertise, and services, Revvity is reshaping possibilities in healthcare, with a focus on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, and informatics. With over $2.7 billion in revenue in 2023 and a workforce of more than 11,000 employees, Revvity serves customers globally across pharmaceuticals, biotech, diagnostic labs, academia, and governments. As part of the S&P 500 index, Revvity has a presence in over 190 countries.
